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Extramammary Paget’s disease (EMPD) is a rare, slow-growing, cutaneous adenocar-
cinoma that usually originates in the anogenital area and axillae outside the mammary 
glands. EMPD mostly progresses slowly and is often diagnosed as carcinoma in situ; 
however, upon becoming invasive, it promptly and frequently metastasizes to regional 
lymph nodes, leading to subsequent distant metastasis. To date, several chemotherapy 
regimens have been used to treat metastatic EMPD; however, they present limited 
effect and patients with distant metastasis exhibit a poor prognosis. Recently, basic and 
translational investigative research has elucidated factors and molecular mechanisms 
underlying the promotion of metastasis, which can lead to targeted therapy-based 
emerging treatment strategies. Here, we aim to discuss current therapies and their 
limitations; advancements in illustrating mechanisms promoting invasion, migration, 
and proliferation of EMPD tumor cells; and future therapeutic approaches for metastatic 
EMPD that may enhance clinical outcomes.
Keywords: metastatic extramammary Paget’s disease, HeR2–Pi3K/eRK signaling, lymphangiogenesis, CXCR4–
stromal cell-derived factor-1 axis, CD163+M2 macrophage, receptor activator of nuclear factor kappa-B ligand–
RAnK signaling, mismatch-repair deficient, anti-PD-1 antibody
invASive eXTRAMAMMARY PAGeT’S DiSeASe (eMPD) 
THeRAPeUTiC CHALLenGe: PRevenTinG AnD TReATinG 
TUMOR MeTASTASiS
Extramammary Paget’s disease is a rare, slow-growing, cutaneous adenocarcinoma that manifests 
as an erythematous, eczematous plaque outside the mammary gland, occasionally accompanied by 
hypopigmented patches. EMPD affects apocrine gland-rich sites such as the anogenital area and 
axillae. Despite requiring broad local resection for the treatment of a primary lesion because of 
the frequent microscopic extensions and less common satellite lesions beyond the clinical tumor 
border (1), the prognosis of patients with EMPD is usually good because tumor cells are in the 
radial growth phase for a prolonged duration, and a majority of cases are treated in the stage of 
carcinoma in situ (2).
However, once EMPD invades into the dermis and becomes invasive EMPD, tumor cells gain 
high metastatic potential, leading to the development of lymph node (LN) metastasis even in patients 
with dermal microinvasion (3). Besides, over one-third of patients with LN metastasis consequently 
develop distant metastasis (4). To date, several chemotherapeutic regimens (Table 1), such as low-
dose 5-fluorouracil (5-FU)/cisplatin (FP), FECOM (5-FU, epirubicin, carboplatin, vincristine, and 
mitomycin C), docetaxel monotherapy, S-1 monotherapy, docetaxel and S-1 combination therapy, 
TABLe 1 | Current systemic therapy for metastatic extramammary Paget’s disease in case studies and case reports.
Reference no. of 
patients
Treatment Type of response Outcome (months)
Tokuda et al. (5) 22 Low-dose FP (5-FU, cisplatin) CR (1/22), PR (12/22), SD (6/22), 
PD (3/22)
PFS: median 5.2, OS: median 12.0
Oashi et al. (6) 7 FECOM (5-FU, epirubicin, carboplatin, vincristine, 
mitomycin C)
PR (4/7), unevaluable (3/7) PFS: median 6.5, OS: median 9.4
Yoshino et al. (7) 13 Docetaxel PR (8/13), SD (3/13), PD (2/13) PFS: median 7.1, OS: median 16.6
Mikoshiba et al. (8) 1 S-1 PR PFS: 36
Kato et al. (9) 2 S-1 PR PFS: 5, 11+
Matsushita et al. (10) 1 Docetaxel + S-1 PR PFS: 15+
Ogata et al. (11) 1 Docetaxel + S-1 PR PFS: 12+
Egashira et al. (12) 2 Docetaxel + S-1 CR (1/2), PR (1/2) PFS: 12, 10, OS: 26, 23
Hirai and Funakoshi (13) 2 PET (cisplatin, epirubicin, paclitaxel) PR (2/2) PFS: 14+, 12+
Karam et al. (24) 1 Trastuzumab PR PFS: 12
Wakabayashi et al. (27) 1 Trastuzumab PR PFS: 12+
Barth et al. (28) 1 Trastuzumab CR PFS: 12+
Takahagi et al. (25) 1 Trastuzumab + paclitaxel PR PFS: 17, OS: 25
Hanawa et al. (26) 1 Trastuzumab + paclitaxel PR PFS: 13
Ichiyama et al. (29) 1 Trastuzumab + paclitaxel PR PFS: 24+
Yoneyama et al. (45) 1 Bicalutamide + leuprolide acetate PR PFS: 6, OS:14
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival; +, ongoing response; 5-FU, 
5-fluorouracil.
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and PET (cisplatin, epirubicin, and paclitaxel), have been used to 
treat metastatic EMPD (5–13); however, few patients overcome 
tumor recurrence despite tumors in over half of patients’ initially 
responding to these regimens. In addition, the overall survival 
(OS) starts declining from 10 months after starting chemotherapy 
(7), and patients with EMPD with distant metastasis exhibit a 
poor prognosis with the median OS of 1.5 years and 5-year sur-
vival rate of 7% (4). Hence, exploring novel therapeutic strategies 
to prevent and treat metastatic EMPD is imperative.
Metastasis is a multistage process that comprises tumor cell 
invasion, venous/lymphatic intravasation, transit in the vessels, 
venous/lymphatic extravasation, and proliferation at a new site 
(14). Recently, some studies have identified that the protein 
expression of molecules involved in proliferation and survival, 
including HER2 and mTOR, in the Paget cell (tumor cell of EMPD) 
is associated with invasiveness, metastasis, and OS (15–17). 
Similarly, translational research studies have demonstrated that 
cytokines, chemokines, and immune cells in EMPD confer favo-
rable microenvironment for Paget cells to invade, migrate, and 
proliferate, thereby promoting metastasis (18–21). The results of 
current study support that the involvement of both Paget cells and 
tumor microenvironment factors is essential for metastasis; thus, 
the understanding of both aspects provides opportunities for the 
treatment of metastatic EMPD.
HeR2–Pi3K/eRK SiGnALinG in eMPD
In the past, several EMPD studies have focused on investigating 
the HER2–PI3K/ERK signaling in EMPD because it is charac-
terized by the presence of Paget cells, large round, vacuolated, 
pale-staining cells, as mammary Paget’s disease (MPD) and the 
clinical success in targeting aberrant receptor tyrosine kinase 
signaling pathways in breast cancer. Both immunohistochemis-
try and fluorescence in situ hybridization studies of primary and 
LN metastatic lesions have revealed the HER2 overexpression 
(HER2 score of 3+ or 2+) in 15–58% of patients with EMPD 
and that all cases with a HER2 score of 3+ had amplified ERBB2, 
the gene encoding HER2 (16, 22). Of note, a HER2 score of 3+ 
or 2+ was significantly more common in patients with deeply 
invasive EMPD that those with in  situ/superficial invasive (in 
which tumor invasion was limited to the papillary dermis) 
EMPD and was correlated with numerous LN metastases (16). 
Furthermore, about 90% of patients exhibited no difference in 
the HER2 protein overexpression and ERBB2 gene amplification 
between primary tumors and corresponded LN metastasis (23), 
suggesting that HER2’s contribution to the pathogenesis and 
progression in a subset of metastatic EMPD and implying the 
possibility that HER2 blockade disrupts the progression of both 
primary and metastatic lesions of this population. In corrobora-
tion with the hypothesis, six case reports determined that both 
primary and metastatic lesion of HER2-overexpressed EMPD 
responded well and attained partial or complete response for 
6 months to 2 years by anti-HER2 antibody, trastuzumab alone, 
or trastuzumab with paclitaxel (Table  1) (24–29). A phase 2 
study of trastuzumab with docetaxel for HER2-positive unre-
sectable or metastatic EMPD (UMIN000021311) is ongoing 
based on these results.
HER2 activates several signaling pathways such as the RAS–
RAF–MEK–ERK pathway and PI3K–AKT–mTOR pathway, 
which accelerate cell growth and increase cell survival (30). A 
study demonstrated that 28 and 56% of HER2-overexpressed 
EMPD cases presented high expression of phosphorylated ERK 
and phosphorylated AKT, respectively, with high Ki-67 labeling 
index (31). However, the high expression of phosphorylated ERK 
and phosphorylated AKT was also noted in 30 and 33% of EMPD 
patients without the HER2 overexpression, respectively, but with 
high Ki-67 labeling index (31). In addition, other studies have 
demonstrated that Ki-67, as well as mTOR, was expressed at 
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significantly higher levels in invasive cases than carcinoma in situ 
cases (17, 32). Furthermore, the DNA sequencing of EMPD study 
revealed that 19% of cases comprised mutant RAS or RAF genes 
and 35% of cases had mutations in PIK3CA (which encodes the 
catalytic subunit of PI3K) or AKT1 that activate those pathways 
(33). In particular, cases with mutations in both RAS/RAF and 
PIK3CA/AKT1 signaling pathways were sporadic, and a mutu-
ally exclusive pattern was observed (33). Overall, these results 
highlight that not only HER2 but also the activation of down-
stream molecules in the RAS–RAF–MEK or PI3K–AKT–mTOR 
pathways could contribute to the progression of EMPD. Notably, 
all mutations detected in RAF were BRAF V600E that can be 
inhibited by vemurafenib or dabrafenib, the Food and Drug 
Administration (FDA)-approved drugs for metastatic melanoma 
(33). In addition, multiple drugs targeting the RAS–RAF–MEK 
and PI3K–AKT–mTOR pathways have passed through clinical 
trials and are used for other cancers. Hence, multiple treatment 
options exist for developing novel therapeutics that target patients 
with metastatic EMPD with the aberrant RAS–RAF–MEK or 
PI3K–AKT–mTOR signaling (Figure 1A).
The HER family comprises four type 1 transmembrane 
tyrosine kinase receptors, HER1 (or EGFR), HER2, HER3, and 
HER4 (34). Of these, HER2 dimerizes with other members of 
the HER family, and the dimerization of HER2:HER3 dimers 
was proven to be the most oncogenic receptor pairing that 
activates the RAS–RAF–MEK and PI3K–AKT–mTOR pathways 
in HER2-positive breast cancer cells (35). Hence, pertuzumab, 
an anti-HER2 antibody that inhibits dimerization with HER1, 
HER3, and HER4, in combination with trastuzumab and doc-
etaxel attained a significantly longer progression-free survival 
and OS in untreated HER2-positive metastatic breast cancer 
compared to trastuzumab plus docetaxel alone; the former regi-
men is now preferred as the first-line treatment of patients with 
HER2-positive metastatic breast cancer (36, 37). However, the 
expression of HER1, HER3, and HER4 has never been detected 
in EMPD as well as in MPD, and targeting the dimerization of 
HER2 is unlikely to prove clinical significance in HER2-positive 
metastatic EMPD (38, 39).
HORMOne ReCePTORS SiGnALinG  
in eMPD
Signaling through hormone receptors contributes to the tumor 
development and progression in some cancer types such as 
breast cancer. More than two-thirds of breast cancers express 
estrogen receptor (ER), and research has proved that ER-targeted 
therapy reduces relapse and improves the OS in advanced breast 
cancer (40). However, MPD expresses ER only in 10% of cases 
despite being one of the types of breast cancer. Similarly, EMPD 
also demonstrates a low ER-positive rate at 4% (41). In fact, both 
MPD and EMPD exhibit a high androgen receptor (AR)-positive 
rate at 54–90%. In addition, another study reported that the AR 
expression intensity was significantly higher in invasive EMPD 
than noninvasive EMPD (41–43). Furthermore, the expression 
intensity of 5α-reductase and 17β-hydroxysteroid dehydroge-
nase type 5, enzymes producing androgen, was higher in invasive 
EMPD than noninvasive EMPD, suggesting the possibility of 
androgen amplification and the association of the androgen–AR 
signaling with the progression of EMPD (Figure 1A) (43, 44). In 
corroboration with the hypothesis, one case report demonstrated 
that the combined androgen blockade (CAB) therapy by bicalu-
tamide (an anti-androgen drug) and leuprolide acetate (LH–RH 
agonist), used in the treatment of prostate cancer, can signifi-
cantly reduce multiple bone metastases of EMPD (45). Although 
the effect of CAB lasted only for 6 months, it did not cause severe 
bone marrow suppression; hence, androgen-deprivation therapy 
could be one of the potential therapeutic approaches for meta-
static EMPD.
LYMPHAnGiOGeneSiS AnD ePiTHeLiAL–
MeSenCHYMAL TRAnSiTiOn (eMT)  
OF PAGeT CeLLS in eMPD
The clinical manifestation of erythematous, eczematous plaque 
of EMPD indicates the presence of vasodilation and hyperemia 
in the dermis of EMPD lesion. In fact, the histology of in situ 
and invasive EMPD lesions demonstrates a prominent enlarge-
ment and formation of several lymphatic and blood vessels in 
the dermis compared to those of healthy skin or other skin 
cancers such as melanoma (18). The immunohistochemical 
analysis established the expression of VEGF-A in Paget cells, as 
well as macrophages, and VEGF-C was also expressed in Paget 
cells (18). Both VEGF-A and VEGF-C are renowned cytokines 
related to angiogenesis and lymphangiogenesis, and evidence 
suggests that the generation of new blood and lymphatic vessels 
is crucial in cancer metastasis (46). Intriguingly, the immuno-
histochemical analysis also revealed that lymphatic endothelial 
cells (LECs) in a primary lesion express stromal cell-derived fac-
tor-1 (SDF-1), and N-cadherin-positive Paget cells co-expresses 
CXCR4, a specific ligand of SDF-1 (18). Notably, N-cadherin, 
vimentin, and snail are molecules that are upregulated in the 
EMT, a process through which epithelial cells lose their polarity, 
cell–cell adhesion, and E-cadherin expression, and TGF-β1 can 
induce EMT (47). A functional in  vitro study using a human 
squamous carcinoma cell line corroborated with human patho-
logical findings and revealed that snail increases the CXCR4 
expression on tumor cells in the presence of TGF-β1 and the 
EMT process augments tumor cell migration through the 
CXCR4–SDF-1 axis (Figure 1B) (18). Furthermore, the CXCR4 
expression of Paget cells in the primary lesion correlated with 
the presence of LN metastasis and reduced the disease-specific 
survival (18, 48). Likewise, the N-cadherin and vimentin expres-
sion of Paget cells in the primary lesion also correlated with the 
reduced OS (18). Hence, these findings implicate a crucial role 
of lymphangiogenesis and EMT of Paget cells in promoting LN 
metastasis of EMPD, and blocking the CXCR4–SDF-1 axis can 
be a novel option of adjuvant therapy for patients with CXCR4-
positive invasive EMPD to prevent LN metastasis. Furthermore, 
the blockade of mutated PIK3CA or AKT1 might be an effec-
tive adjuvant therapy because the DNA sequencing of EMPD 
revealed a correlation of PIK3CA and AKT1 mutations with 
E-cadherin hypermethylation (33).
FiGURe 1 | Continued
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FiGURe 1 | Signaling pathways involved in the progression of extramammary Paget’s disease. (A) The aberrant activation of HER2, molecules involved in the 
RAS–RAF–MEK–ERK signaling or PI3K–AKT–mTOR signaling promote the proliferation and survival of Paget cells. Likewise, the androgen–androgen receptor (AR) 
signaling can induce the proliferation and survival of Paget cells. Red, Food and Drug Administration-approved drugs for other cancers that target aspects of this 
pathway. (B) The interaction of Paget cells with lymphatic endothelial cells (LECs) through the CXCR4–stromal cell-derived factor-1 (SDF-1) signaling or with 
CD163+Arg1+ M2 macrophages through the receptor activator of nuclear factor kappa-B ligand (RANKL)–RANK signaling facilitates metastasis of Paget cells.
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THe ROLe OF ReCePTOR ACTivATOR  
OF nUCLeAR FACTOR KAPPA-B LiGAnD 
(RAnKL)–RAnK inTeRACTiOn in THe 
TUMOR MiCROenviROnMenT OF eMPD
Although the aberrant activation of a signaling pathway in tumor 
cells and lymphangiogenesis mediates the progression of EMPD, 
the role of other cells, especially immune cells, in the tumor 
microenvironment of EMPD remains unclear. Histologically, 
EMPD exhibits abundant lymphocyte infiltration. The number 
of CD8+ T cell infiltration in noninvasive and invasive EMPD is 
similar; however, the number of CD8+ T  cell-expressing gran-
ulysin and perforin is relatively lower in invasive EMPD than 
that of noninvasive EMPD, signifying the presence of stronger 
immunosuppression in the tumor microenvironment of invasive 
EMPD than noninvasive EMPD (49). Reportedly, invasive EMPD 
comprises a significantly higher number of CD163+Arg1+ M2 
macrophages, an immunosuppressive macrophage, compared to 
noninvasive EMPD (49).
The RANKL and its receptor, RANK signaling, exerts num erous 
effects on immunity and promotes the survival of conventional 
dendritic cells and T-cell priming, thereby generating active 
immune responses (50). By contrast, it controls the number of 
regulatory T cells (Tregs) and induces tolerance against antigens 
(51). In EMPD lesions, Paget cells profoundly express RANKL 
with matrix metalloproteinase-7, which cleaves RANKL to 
release a soluble form (sRANKL), facilitating interaction with 
nearby cells expressing RANK (19). Remarkably, RANK is 
primarily expressed in CD163+Arg1+ M2 macrophages, and 
in vitro studies using monocyte-derived M2 macrophages have 
demonstrated that these cells produce CCL17 and promote the 
migration of CCR4-expressed CD4+ T  cells, which comprise 
effector CD4+ T cells and Tregs when treated with sRANKL (20). 
In line with the in  vitro experiment, CCL17 was co-expressed 
on the CD163+Arg1+ M2 macrophages in invasive EMPD (20). 
Furthermore, a study has reported that effector Tregs comprising 
a robust immunosuppressive effect profoundly express CCR4 
(52) and that increased numbers of Tregs were related to more 
extensive cases of vulvar EMPD and disease recurrence (53). 
These studies highlight the crucial role of CD163+Arg1+ M2 
macrophage and Tregs in establishing an immunosuppressive 
microenvironment in invasive EMPD by the RANKL–RANK 
interaction that promotes EMPD progression and causes poor 
prognosis (Figure 1B).
Reportedly, RANKL binds to RANK on osteoclasts and serves 
as a critical factor for regulating bone remodeling, and the activa-
tion of the RANKL–RANK signaling augments bone metastasis 
of various cancer types such as breast cancer (50). Based on this 
notion, a study demonstrated that denosumab, the anti-RANKL 
antibody, significantly delayed the appearance of skeletal-related 
events compared to bisphosphonates in patients with breast can-
cer with bone metastasis, thereby initiating its use to treat various 
metastatic bone tumors (54). Bone has been known as one of the 
most common site, where EMPD develops distant metastasis 
(55, 56). Based on these findings, denosumab seems not only 
useful for patients with metastatic EMPD and bone metastasis 
but also might be effective from the early stage to prevent the 
progression of invasive EMPD. Furthermore, since RANKL is 
related to immunosuppression of the EMPD microenviron-
ment, denosumab could be a potential to enhance the efficacy of 
immunotherapy.
iMMUnOTHeRAPY FOR MeTASTATiC 
eMPD
Although the response rate is 20–35% in solid cancers, immu-
notherapy with anti-PD-1 antibody is a prominent therapeutic 
approach for cancers. This is because it can induce a durable 
response in a majority of responders for more than 2 years, which 
is uncommon with the molecular targeted therapy (57–60). The 
biomarkers that define anti-PD-1 antibody responders remain 
unclear; however, it was recently revealed that cancer with DNA 
mismatch-repair (MMR) gene mutations, so called “mismatch-
repair-deficient cancer,” significantly responded better to anti-
PD-1 antibody than MMR proficient cancer (61). In addition, it 
was reported that an anti PD-1 antibody induced robust antitumor 
immunity and attained durable disease control in heavily treated 
patients with colorectal cancer with MMR-deficient or microsat-
ellite instability-high (MSI-H) status (62). Overall, these results 
propose that the MMR status or MSI-H is a useful biomarker 
to predict the clinical benefit of anti-PD-1 antibody, serving as 
the basis for the FDA’s approval of an anti-PD-1 antibody for 
unresectable or metastatic MMR-deficient or MSI-H cancers, 
irrespective of cancer’s original location.
The MMR pathway affects removal and correction of DNA 
base mismatches that arise either during DNA replication or 
caused by DNA damage (63). A mutation of genes involved in 
MMR, MLH1, PMS1, MSH2, and MSH6 predispose to several 
tumorigenic conditions, such as Lynch syndrome, and cause 
cancer cells to display MSI-H (63). Although inactivation of 
MMR elevates the mutational burden, thereby promote carcino-
genesis, a recent in vivo functional analysis revealed that it also 
leads to dynamic mutational profiles, resulting in the persistent 
renewal of mutation-associated neoantigens (MANAs) triggering 
durable immunosurveillance that can be further enhanced by an 
anti-PD-1 antibody. By contrast, MMR proficient cells exhibited 
stable mutational load and MANA profiles over time, which was 
consistent with the results of clinical trials (61, 64, 65).
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Extramammary Paget’s disease has long been recognized to 
pose a high risk of developing secondary cancer. Reportedly, 
14–32% of cases have also been diagnosed with other primary 
cancers (66, 67). Kang et  al. hypothesized that MMR gene 
mutations could be associated with the high occurrence of 
secondary cancer in EMPD and investigated the MMR status 
and the presence of gene mutation in MLH1, PMS1, MSH2, and 
MSH6 in 20 patients with EMPD (68). Their results revealed 8 
of 20 cases (40%) with germline MMR genes missense muta-
tions. Of these 8 cases with MMR genes mutations, 1 and 4 cases 
exhibited MSI-high or MSI-lo, respectively, whereas none of the 
other 12 cases without MMR genes mutations exhibited MSI. 
Furthermore, their sequencing analysis of MLH1 and MSH2 
gene for 172 samples identified germline and somatic mutations 
of MLH1 or MSH2 in 34.3 and 13.4% of cases, respectively. 
Of these, MLH1 V384D (15.7%) and MLH1 R217C (4.1%) were 
top two germline mutations, and these detection rates were 
significantly higher than healthy controls. Furthermore, the 
functional in vitro assay revealed that MLH1 V384D and MLH1 
R217C mutations had 50–60% MMR efficiency than wild-type 
MLH1. Although having high tumor mutational burden does 
not always associate with improved survival and clinical trials 
should be conducted to evaluate the survival benefit, these find-
ings suggest that there is a decent percentage of MMR-deficient 
EMPD, which has an impaired MMR machinery, in EMPD and 
this subset of patients might achieve a durable response by anti-
PD-1 immunotherapy.
COnCLUSiOn
Metastatic EMPD is an aggressive skin adenocarcinoma with 
poor prognosis. Since current chemotherapeutic regimens are 
only moderately effective, improving clinical outcomes is impera-
tive. The basic and translational research to date has provided 
an insight into the mechanisms promoting metastasis of EMPD 
that provide potential therapeutic targets for new drug develop-
ment. Seemingly, Paget cells augment the ability of proliferation 
and survival by activating the RAS–RAF–MEK–ERK signaling, 
PI3K–AKT–mTOR signaling, or androgen–AR signaling. In 
addition, the interaction of Paget cells with other cells, such as 
LECs and CD163+Arg1+ macrophages in a tumor through the 
CXCR4–SDF-1 signaling and RANKL–RANK signaling, respec-
tively, could establish a favorable tumor microenvironment to 
promote metastasis of Paget cells. Furthermore, recent genomic 
analysis of MMR has revealed that a decent percentage of EMPD 
comprises MMR-deficient EMPD cases that might achieve 
durable clinical response by an anti-PD-1 antibody. Hence, we 
are now beginning to understand multiple aspects involved in the 
pathogenesis of metastatic EMPD, and these findings will be sure 
to lead to better treatments for patients with metastatic EMPD 
in the future.
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